Pacira BioSciences' Q2 revenue misses estimates

Overview

• Pacira Q2 2025 revenue of $181.1 mln missed analyst expectations, per LSEG data

• Adjusted EPS for Q2 2025 beats consensus, indicating strong operational performance

• Company repurchased 2 mln shares, costing $50 mln, showing confidence in strategy

Outlook

• Pacira narrows 2025 revenue guidance to $730 mln-$750 mln

• Company raises 2025 non-GAAP gross margin forecast to 78-80%

• Pacira reiterates 2025 non-GAAP R&D expense at $90 mln-$105 mln

• Company sees 2025 non-GAAP SG&A expense at $290 mln-$320 mln

Result Drivers

• ZILRETTA EXPANSION - Strategic collaboration with Johnson & Johnson MedTech to expand ZILRETTA's market reach

• MANUFACTURING EFFICIENCIES - Large-scale EXPAREL manufacturing process improves gross margins and inventory management

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 2 "hold" and 1 "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for Pacira Biosciences Inc is $30.00, about 23.5% above its August 4 closing price of $22.94

• The stock recently traded at 7 times the next 12-month earnings vs. a P/E of 9 three months ago

Press Release: ID:nGNX9n8pJv